Medpace Holdings, Inc. Reports Second Quarter 2024 Results

Rhea-AI Summary

Medpace Holdings, Inc. (MEDP) reported strong financial results for Q2 2024. Revenue increased 14.6% to $528.1 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $88.4 million, or $2.75 per diluted share, up from $61.1 million in Q2 2023. The company's net income margin improved to 16.7%, while EBITDA grew 34.2% to $112.3 million.

Medpace's backlog increased 13.7% to $2,924.9 million, and net new business awards were $551.0 million, resulting in a net book-to-bill ratio of 1.04x. The company updated its 2024 financial guidance, forecasting revenue between $2.125 billion and $2.175 billion, representing 12.7% to 15.3% growth over 2023.

Positive

• Revenue increased 14.6% year-over-year to $528.1 million
• GAAP net income grew 44.7% to $88.4 million
• Net income margin improved from 13.3% to 16.7%
• EBITDA increased 34.2% to $112.3 million
• Backlog grew 13.7% to $2,924.9 million
• 2024 revenue guidance forecasts growth of 12.7% to 15.3%

Negative

• Net new business awards decreased 4.1% year-over-year to $551.0 million

Insights

Financial Analyst

The financial results presented by Medpace Holdings, Inc. for the second quarter of 2024 are noteworthy. The 14.6% revenue increase to $528.1 million is a strong indicator of growth, while the improvement in GAAP net income from $61.1 million to $88.4 million demonstrates effective cost management and operational efficiency. The EBITDA growth of 34.2% to $112.3 million further solidifies this positive trend, showing enhanced profitability margins.

However, the decline in net new business awards by 4.1% is a point of concern, reflecting potential challenges in acquiring new contracts. The company's net book-to-bill ratio of 1.04x still indicates more incoming business than outgoing, but the downward trend should be monitored closely.

Long-term, the guidance for 2024 with revenue projected between $2.125 billion and $2.175 billion and GAAP net income forecasted between $361 million and $383 million keeps a positive outlook, but these figures will need to be reassessed quarterly to ensure targets are being met.

Market Research Analyst

The market implications of Medpace's Q2 2024 results are significant. The company's revenue growth of 14.6% and the substantial increase in both net income and EBITDA highlight its competitive positioning in the market. This growth trajectory will likely boost investor confidence, potentially leading to a positive market reaction.

However, the 4.1% decrease in net new business awards might suggest a saturation point or increased competition. It is essential to track if this trend continues, as sustained declines could indicate deeper market penetration issues.

Medpace's robust balance sheet with $510.9 million in cash and cash equivalents provides a cushion for future investments or strategic acquisitions, which might be necessary to maintain growth momentum. Their share repurchase program also indicates a commitment to returning value to shareholders, which could stimulate positive sentiment in the market.

Tech Expert

From a technology and operational efficiency standpoint, Medpace's improved financial performance suggests that their technological integrations and platform efficiencies are contributing positively to their margins. The increase in EBITDA margin from 18.1% to 21.3% implies that recent technological investments or optimizations are yielding tangible results.

Given the significant role of technology in clinical research, continuous investments in data analytics, AI and automation could further enhance Medpace's operational capabilities. This is important as the industry becomes more competitive with advancements in digital health technologies.

Maintaining a high level of technology-driven innovation will be key for Medpace to sustain its growth and improve client satisfaction, which can counterbalance the slight decline seen in net new business awards.

• Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%.
• Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x.
• Second quarter of 2024 GAAP net income was $88.4 million, or $2.75 per diluted share, versus GAAP net income of $61.1 million, or $1.93 per diluted share, for the comparable prior-year period. Net income margin was 16.7% and 13.3% for the second quarter of 2024 and 2023, respectively.
• EBITDA was $112.3 million for the second quarter of 2024, an increase of 34.2% from EBITDA of $83.6 million for the comparable prior-year period, resulting in an EBITDA margin of 21.3%.

CINCINNATI--(BUSINESS WIRE)-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Results

Revenue for the three months ended June 30, 2024 increased 14.6% to $528.1 million, compared to $460.9 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2024 increased 14.7% compared to the second quarter of 2023.

Backlog as of June 30, 2024 increased 13.7% to $2,924.9 million from $2,571.9 million as of June 30, 2023. Net new business awards were $551.0 million, representing a net book-to-bill ratio of 1.04x for the second quarter of 2024, as compared to $574.8 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the second quarter of 2024, total direct costs were $374.3 million, compared to total direct costs of $336.6 million in the second quarter of 2023. Selling, general and administrative (SG&A) expenses were $41.5 million in the second quarter of 2024, compared to SG&A expenses of $39.4 million in the second quarter of 2023.

GAAP net income for the second quarter of 2024 was $88.4 million, or $2.75 per diluted share, versus GAAP net income of $61.1 million, or $1.93 per diluted share, for the second quarter of 2023. This resulted in a net income margin of 16.7% and 13.3% for the second quarter of 2024 and 2023, respectively.

EBITDA for the second quarter of 2024 increased 34.2% to $112.3 million, or 21.3% of revenue, compared to $83.6 million, or 18.1% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the second quarter of 2024 increased 33.3% from the second quarter of 2023.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

Year-to-Date 2024 Financial Results

Revenue for the six months ended June 30, 2024 was $1,039.1 million, and increased 16.1% on a reported basis and 16.1% on a constant currency basis from the comparable prior-year period. Year-to-date 2024 GAAP net income was $190.9 million, or $5.96 per diluted share, compared to $134.0 million, or $4.20 per diluted share, for the comparable prior-year period. Year-to-date 2024 EBITDA was $227.9 million, or 21.9% of revenue, and increased 29.1% on a reported basis and 28.5% on a constant currency basis from the comparable prior-year period.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $510.9 million at June 30, 2024, and the Company generated $116.4 million in cash flow from operating activities during the second quarter of 2024. There were no share repurchases in the second quarter of 2024. As of June 30, 2024, the Company had $308.8 million remaining under its authorized share repurchase program.

2024 Financial Guidance

The Company forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion, representing growth of 12.7% to 15.3% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $361.0 million to $383.0 million. Additionally, full year 2024 EBITDA is expected in the range of $430.0 million to $460.0 million. Based on forecasted 2024 revenue of $2.125 billion to $2.175 billion and GAAP net income of $361.0 million to $383.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.24 to $11.93. This guidance assumes a full year 2024 tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after June 30, 2024.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Tuesday, July 23, 2024, to discuss its second quarter 2024 results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries as of June 30, 2024.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “anticipate,” “project,” “goal,” “objective,” “potential,” “range,” “estimate,” “preliminary,” “opportunity,” “outlook,” “trend,” “can,” “might,” “drives,” “hope,” “predict” and similar expressions, and variations or negatives of these words. However, the absence of these words does not mean that a statement is not forward-looking.

These forward-looking statements are largely based on management’s current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit experienced personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions, including inflation, in the markets in which we operate, including financial market conditions; the impact of unfavorable economic conditions, including conditions caused by the uncertain international economic environment and current and future international conflicts; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; and the impact of industry-wide reputational harm to CROs. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all important factors on our business or the extent to which any factor, or combination of such factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

These and other important factors discussed under the caption “Risk Factors” in Item 1A, Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest expense, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands, except per share amounts)	Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Revenue, net	$	528,104			$	460,868			$	1,039,148			$	894,942
Operating expenses:
Direct service costs, excluding depreciation and amortization		171,541				158,526				343,033				309,594
Reimbursed out-of-pocket expenses		202,725				178,025				387,135				330,842
Total direct costs		374,266				336,551				730,168				640,436
Selling, general and administrative		41,453				39,404				85,534				77,431
Depreciation		6,874				5,970				13,505				11,378
Amortization		361				550				722				1,100
Total operating expenses		422,954				382,475				829,929				730,345
Income from operations		105,150				78,393				209,219				164,597
Other income (expense), net:
Miscellaneous (expense) income, net		(133	)			(1,283	)			4,460				(596	)
Interest income (expense), net		5,465				(1,366	)			9,585				(2,227	)
Total other income (expense), net		5,332				(2,649	)			14,045				(2,823	)
Income before income taxes		110,482				75,744				223,264				161,774
Income tax provision		22,131				14,676				32,322				27,812
Net income	$	88,351			$	61,068			$	190,942			$	133,962
Net income per share attributable to common shareholders:
Basic	$	2.85			$	2.00			$	6.17			$	4.35
Diluted	$	2.75			$	1.93			$	5.96			$	4.20
Weighted average common shares outstanding:
Basic		30,990				30,537				30,917				30,771
Diluted		32,086				31,575				32,046				31,864

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except share amounts)
	As of
	June 30, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	510,894			$	245,449
Accounts receivable and unbilled, net		301,108				298,400
Prepaid expenses and other current assets		60,521				49,979
Total current assets		872,523				593,828
Property and equipment, net		122,394				120,589
Operating lease right-of-use assets		134,001				144,801
Goodwill		662,396				662,396
Intangible assets, net		35,087				35,809
Deferred income taxes		75,196				74,435
Other assets		18,451				24,970
Total assets	$	1,920,048			$	1,656,828
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	27,388			$	31,869
Accrued expenses		292,659				292,961
Advanced billings		638,417				559,860
Other current liabilities		34,624				40,441
Total current liabilities		993,088				925,131
Operating lease liabilities		131,796				142,122
Deferred income tax liability		2,294				2,404
Other long-term liabilities		29,271				28,221
Total liabilities		1,156,449				1,097,878
Commitments and contingencies
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023		—				—
Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2024 and December 31, 2023; 31,001,549 and 30,752,292 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		310				308
Treasury stock - 70,073 and 70,573 shares at June 30, 2024 and December 31, 2023, respectively		(12,235	)			(12,322	)
Additional paid-in capital		818,903				802,681
Accumulated deficit		(30,790	)			(221,645	)
Accumulated other comprehensive loss		(12,589	)			(10,072	)
Total shareholders’ equity		763,599				558,950
Total liabilities and shareholders’ equity	$	1,920,048			$	1,656,828

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Amounts in thousands)	Six Months Ended June 30,
		2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	190,942			$	133,962
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		13,505				11,378
Amortization		722				1,100
Stock-based compensation expense		7,898				10,344
Noncash lease expense		11,461				9,659
Deferred income tax benefit		(919	)			(3,709	)
Other		(3,903	)			(899	)
Changes in assets and liabilities:
Accounts receivable and unbilled, net		(2,714	)			(21,734	)
Prepaid expenses and other current assets		(11,251	)			(11,831	)
Accounts payable		(2,453	)			2,341
Accrued expenses		915				21,259
Advanced billings		78,557				27,828
Lease liabilities		(11,025	)			(9,379	)
Other assets and liabilities, net		(2,661	)			(7,725	)
Net cash provided by operating activities		269,074				162,594
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures		(18,368	)			(17,959	)
Other		8,108				(11	)
Net cash used in investing activities		(10,260	)			(17,970	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercises		8,326				4,127
Repurchases of common stock		—				(144,020	)
Proceeds from revolving loan		—				105,000
Payments on revolving loan		—				(100,000	)
Net cash provided by (used in) financing activities		8,326				(134,893	)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		(1,695	)			1,142
INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		265,445				10,873
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period		245,449				28,265
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$	510,894			$	39,138

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)
(Amounts in thousands)	Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
RECONCILIATION OF GAAP NET INCOME TO EBITDA
Net income (GAAP)	$	88,351			$	61,068			$	190,942			$	133,962
Interest (income) expense, net		(5,465	)			1,366				(9,585	)			2,227
Income tax provision		22,131				14,676				32,322				27,812
Depreciation		6,874				5,970				13,505				11,378
Amortization		361				550				722				1,100
EBITDA (Non-GAAP)	$	112,252			$	83,630			$	227,906			$	176,479
Net income margin (GAAP)		16.7	%			13.3	%			18.4	%			15.0	%
EBITDA margin (Non-GAAP)		21.3	%			18.1	%			21.9	%			19.7	%

FY 2024 GUIDANCE RECONCILIATION (UNAUDITED)
(Amounts in millions, except per share amounts)	Forecast 2024
	Net Income								Net income per diluted share
	Low				High				Low				High
Net income and net income per diluted share (GAAP)	$	361.0			$	383.0			$	11.24			$	11.93
Income tax provision		63.7				71.7
Interest income, net		(24.0	)			(24.0	)
Depreciation		27.9				27.9
Amortization		1.4				1.4
EBITDA (Non-GAAP)	$	430.0			$	460.0

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722495929/en/

Investor Contact:

Lauren Morris

513.579.9911 x11994

l.morris@medpace.com

Media Contact:

Julie Hopkins

513.579.9911 x12627

j.hopkins@medpace.com

Source: Medpace Holdings, Inc.

FAQ

What was Medpace's (MEDP) revenue for Q2 2024?

Medpace's revenue for Q2 2024 was $528.1 million, representing a 14.6% increase from the comparable prior-year period.

How much did Medpace's (MEDP) GAAP net income grow in Q2 2024?

Medpace's GAAP net income for Q2 2024 grew to $88.4 million, or $2.75 per diluted share, up from $61.1 million, or $1.93 per diluted share, in Q2 2023.

What is Medpace's (MEDP) revenue forecast for 2024?

Medpace forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion, representing growth of 12.7% to 15.3% over 2023 revenue.

What was Medpace's (MEDP) backlog as of June 30, 2024?

Medpace's backlog as of June 30, 2024, increased 13.7% to $2,924.9 million from $2,571.9 million as of June 30, 2023.

What was Medpace's (MEDP) EBITDA for Q2 2024?

Medpace's EBITDA for Q2 2024 increased 34.2% to $112.3 million, representing 21.3% of revenue.